 |
|
 |
|
|
|
 |
|
February 21, 2008
Talecris Biotherapeutics Celebrates 20th Anniversary of Launch of Prolastin®
Milestone for market-leading Alpha-1 treatment marked by expanding commitment.
|
|
|
|
February 13, 2008
Talecris Plasma Resources Reports Solid Progress Developing Plasma Collection Capabilities
Over the course of the past year, the company has opened 14 new centers throughout the United States and acquired three additional centers.
|
|
|
|
January 31, 2008
Prolastin.com Receives Gold Award from Association of Marketing and Communication Professionals
Talecris honored for outstanding achievement in Web site development.
|
|
|
|
November 12, 2007
www.Prolastin.com Named Best Biotechnology Web Site of 2007
Talecris Biotherapeutics recognized for outstanding achievement in Web development.
|
|
|
|
September 18, 2007
Study Demonstrates Aerosolized Prolastin® Using Unique Nebulizer Results in High Levels of Drug Deposited in Peripheral Regions of Lungs
Encouraging results bolster Talecris' ongoing alpha1-antitrypsin aerosol delivery development program.
|
|
|
|
February 01, 2007
Talecris Biotherapeutics supports projects in the field of alpha1-antitrypsin Deficiency with eALTA fellowships
European alpha1-antitrypsin Laurell’s Training Award (eALTA) 2007 submission process has started.
|
|
|
|
September 05, 2006
Pathogen Safety Reconfirmed for Prolastin®
Manufacturing process removes or inactivates known and emerging pathogens.
|
|
|
|
September 05, 2006
Extensive Post-License Data Reaffirm Clinical Safety Profile of Prolastin®
Data set from 18 years of experience represents largest and longest among alpha1-antitrypsin augmentation therapies.
|
|
|
|
May 22, 2006
Landmark Alpha-1 Historical Medical Literature Available from Talecris Biotherapeutics
Compendium of classic papers compiled in honor of 20-year history of Prolastin®.
|
|
|
|
October 4, 2005
Talecris Biotherapeutics Receives QSEAL Certification from PPTA
Independent industry organization recognizes Talecris' commitment to providing patients with safe and high-quality therapeutic protein therapies.
|
|
|
|
September 27, 2005
Talecris Biotherapeutics proudly announces the recipients of the 2005 ALTA awards
Fellowships to support research in alpha1-antitrypsin Deficiency (genetic emphysema) to improve diagnosis, care, and treatment of people with Alpha-1
|
|
|
|
August 9, 2005
Talecris Biotherapeutics and BBI Sign Development Agreement for Alpha-1 Antitrypsin Test
Talecris and BBI aim to provide accurate, fast method of testing alpha1-antitrypsin (AAT) levels.
|
|
|
|
April 1, 2005
Announcing the Launch of Talecris Biotherapeutics: Combining a Proud History of Patient Care with a Bold New Vision
Talecris to apply innovative approach to its inherited, 60-year legacy of providing life-saving and life enhancing plasma-derived therapeutic proteins
2nd Annual International Alpha-1 Patient Congress
Continuing our commitment to the global alpha-1 community, we were proud to be a Gold Sponsor of the 2nd International Alpha-1 Patient Congress held in Dublin, Ireland, October 2004. This congress, organized by the Alpha-1 International Network, convened alpha-1 patients, caregivers, and treaters from around the world in an effort to increase communication and collaboration among support groups globally. Presented information included updates on the latest research and disease management techniques. Additionally, representatives from each country provided an overview of challenges and opportunities in their regions allowing attendees to gain a more global perspective on alpha-1.
|
For more information about the Alpha-1 International Network, please contact:
Larry Warren, President, Alpha-1 International Network
Dublin, Ireland
email: larryw@connect.ie
The Alpha-1 Foundation and Alpha-1 Association run an extensive series of Alpha-1 and COPD education days around the country.
For information on upcoming dates and to find a meeting in your area, please
click here.
Important Safety Information
Prolastin®, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Weekly Prolastin® therapy has demonstrated a low occurrence of side effects. In clinical studies with Prolastin®, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%). As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click here for Prolastin® full Prescribing Information.
Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor or healthcare provider if you have any questions about your health or any of your medications.
|
|
|
|
|